|
|
 |
| Àâòîðèçàöèÿ |
|
|
|
| Ïîèñê ïî óêàçàòåëÿì |
|
|
|
|
|
|
|
 |
|
|
|
| Lanza R. (ed.), Weissman I. (ed.), Thomson J. (ed.) — Handbook of Stem Cells (vol. 1) Embryonic Stem Cells |
|
|
|
| Ïðåäìåòíûé óêàçàòåëü |
CBP/p300 2: 107 2:
CCAAT/enhancer binding proteins 1: 329
CD 10 cells, common lymphoid progenitor phenotype 2: 350—351
CD 10 cells, lymphoid potential 2: 349
CD105 cells 2: 427
CD133 antigen 2: 617
CD166 cells 2: 427
CD25 cells 1: 679
CD26 cells 2: 184
CD29 cells 2: 749
CD3 cells, immune reconstitution by HS cell implant 2: 751 2:
CD3 cells, T cell expression 1: 676 1: 2:
CD31 cells 2: 162—163 2:
CD34 cells 2: 14
CD34 cells as hematopoietic stem cell marker 2: 323—324 2: 2: 2: 2: 2: 2: 2:
CD34 cells in hematopoietic development 2: 160 2: 2: 2: 2:
CD34 cells in hematopoietic stem cell transplantation 2: 688
CD34 cells in umbilical cord blood 2: 182—183
CD34 cells in vascular development 1: 323 1:
CD34 cells, common lymphoid progenitor phenotype 2: 350—351
CD34 cells, gene expression profile 2: 89 2:
CD34 cells, immune reconstitution by HS cell implant 2: 752
CD34 cells, lymphoid potential 2: 349—350
CD34 cells, satellite cells 2: 398
CD34 cells, slide population 2: 26
CD34 cells, very late antigen expression in 2: 597
CD38 cells in hematopoietic development 2: 161
CD38 cells in umbilical cord blood 2: 182—183
CD38 cells, common lymphoid progenitor phenotype 2: 350—351
CD4 cells in graft rejection 1: 666
CD4 cells in T cell formation 2: 745—746
CD4 cells, age-related changes 2: 749
CD4 cells, development and function 1: 679
CD4 cells, immune reconstitution by HS cell implant 2: 751 2: 2:
CD4 cells, lymphoid potential 2: 349—350
CD4 cells, T cell expression 1: 676 1:
CD41 cells 2: 160—161
CD44 cells 2: 160
CD44 cells in hematopoietic development 2: 598
CD45 cells in hematopoietic development 2: 161 2: 2:
CD45 cells in T cell formation 2: 746
CD45 cells, age-related changes 2: 749
CD45 cells, expression in muscle-derived hematopoietic stem cells 2: 405—407
CD45 cells, immune reconstitution by HS cell implant 2: 751 2: 2:
CD45 cells, nonhematopoietic gene expression 2: 362
CD49 cells 2: 428—429
CD7 cells 2: 350—351
CD8 cells in graft rejection 1: 666
CD8 cells in T cell formation 2: 745—746
CD8 cells, age-related changes 2: 749
CD8 cells, immune reconstitution by HS cell implant 2: 751 2: 2:
CD8 cells, precursors 2: 361
CD8 cells, T cell expression 1: 676 1:
cDNA sequencing, microarray analysis 2: 28 2: 2: 2:
cDNA sequencing, serial analysis of gene expression 2: 28—29
Cdx genes 2: 533—534
Cell adhesion in epidermal stem cell differentiation 2: 251
Cell adhesion in hematopoietic stem cell mobilization and homing 2: 597—598
Cell adhesion in olfactory system 2: 233
Cell adhesion in stem cell niche functioning 2: 62—63 2:
Cell banks 2: 808—809
Cell cycle in vivo kinetics 2: 73—74 (see also “Embryonic stem (ES) cells cell “Gl “G2
Cell cycle, aging effects 2: 338
Cell cycle, checkpoints 2: 116—118 2: 2:
Cell cycle, checkpoints, overriding 2: 120—121
Cell cycle, clinical significance 2: 73 2:
Cell cycle, cyclins and Cdk complexes in 2: 73 2: 2:
Cell cycle, donor-recipient compatibility in cloning 1: 123 1:
Cell cycle, ex vivo stem cell expansion 2: 74
Cell cycle, hematopoietic stem cells 2: 115—121
Cell cycle, progenitor cell pool in 2: 73—74
Cell cycle, stem cell regulation 2: 73—78
Cell fusion in somatic cell nuclear transfer 1: 624—625
Cell fusion in tumor formation 1: 112 2:
Cell fusion of differentiated phenotypes 1: 111—112
Cell fusion of pluripotent cells 1: 112—113
Cell fusion, conditions for 2: 153
Cell fusion, early research 2: 153—154
Cell fusion, epigenetic reprograming by ES cells 2: 295
Cell fusion, frequency in culture 2: 154
Cell fusion, hybrid vigor 2: 154
Cell fusion, intracellular 2: 153
Cell fusion, multipotent adult progenitor cells 2: 295
Cell fusion, normal in vivo 1: 114—115
Cell fusion, reprogramming somatic cell nuclei with cytoplasm of pluripotent cells 1: 113—114
Cell fusion, stem cell plasticity and 1: 114—115
Cell fusion, techniques 1: 111
Cell fusion, therapeutic implications 2: 155—156
Cell fusion, types of 2: 153
Cell fusion, vs. cell transdifferentiation 2: 16 2: 2: 2: 2: 2:
Cell fusion, Y-chromosome hybridization 2: 15
Cementoblasts 2: 284
Cementum 2: 279 2: 2:
Center for Biologies Evaluation and Research 2: 804 2: 2:
Center for Biologies Evaluation and Research, regulatory approach 1: 775—785
Central nervous system 1: 237—247
Central nervous system, adult stem cell population 2: 219—222
Central nervous system, cell cycle regulation 2: 74
Central nervous system, cell fate determinants 1: 237 1: 2:
Central nervous system, development 1: 205—214 1: 1: 2: 2:
Central nervous system, development, vertebrate neurogenesis 1: 205—214
Central nervous system, disorders of 1: 245—247
Central nervous system, injury response 2: 698
Central nervous system, multipotent adult progenitor cell implantation 2: 295
Central nervous system, neurogenesis 2: 219—221
Central nervous system, patterning 2: 192—197
Central nervous system, progenitor cells 2: 191
Central nervous system, promoting intrinsic repair 2: 698—699
Central nervous system, regenerative capacity 2: 219 2: 2: 2:
Central nervous system, retinal regeneration 2: 704—706
Central nervous system, stem cell therapy 1: 709
Central nervous system, stem cell therapy, challenges 2: 695—696
Central nervous system, stem cell therapy, future prospects 2: 699
Central nervous system, stem cell therapy, inductive signaling issues 2: 698
Central nervous system, stem cell therapy, manipulation of cells for 2: 697—698
Central nervous system, stem cell therapy, sources of cells for 2: 696—697
Central nervous system, therapeutic interventions 2: 221—222 (see also “Neural stem cells” “Neurons” “Spinal
Centrosomes 1: 175—176
Centrosomin 1: 175
Cerebrovascular infarction 1: 246
Chemical mutagenesis 1: 599—601
Chemical mutagenesis, future research 1: 605—606
Chemical mutagenesis, library of mutagenized cells 1: 602—603 1:
Chemical mutagenesis, screening for 1: 601—602 1:
Chemokine-induced stem cell mobilization 2: 595—596 2:
Chemotherapy 2: 621—622
Cholangiocytes 2: 497—498
Chondrocytes, bone development 2: 415 2:
Chondrocytes, differentiation 1: 288—289
Chondrocytes, function 1: 285
Chondrocytes, growth factors 2: 774
Chondrocytes, processed lipoaspirate cells in formation of 2: 434—436 2:
Chondrocytes, tissue engineering 2: 773—775
Chondrocytes, Xenopus animal cap culture 1: 489f
Chorioallantoic placenta 1: 194 1:
Chorioallantoic placenta, signaling pathways in 1: 197
Chorion 1: 194 1:
Chromatin in cell self-renewal 2: 27
Chromatin in epiblast formation 1: 129
Chromatin, ATPase chromatin-remodeling complexes 1: 70—72 1:
Chromatin, biological significance 1: 63—67
Chromatin, cell remodeling 2: 148
Chromatin, chromatin-modifying protein knockout mice phenotypes 1: 65—66t
Chromatin, DNA methylation 1: 68—69 1:
Chromatin, epigenetic processes in modification of 1: 72—81 1:
Chromatin, histone modification 1: 69—70 2:
Chromatin, Hoescht—33342 staining 2: 330
Chromatin, structure 1: 63 1: 2:
Chromosomal engineering 1: 618—620 1:
Chromosome condensation 2: 148
| Chronic myeloid leukemia 1: 280 2: 2:
Churchill gene 1: 138 1:
Ciliary marginal zone 1: 253
Ciliary neurotrophic factor (CNTF) 1: 28
Ciliary neurotrophic factor (CNTF) in gp30/gpl30 dimerization 1: 28—29
Clara cell secreting proteins 2: 552
Clara cells 2: 548
Clinical trials 1: 776
Clonal analysis techniques 2: 651—658 2:
Cloning, chromatin role in 1: 64—67
Cloning, defining characteristics 2: 2
Cloning, developmental defects in 1: 63—64
Cloning, early research 1: 626 2:
Cloning, epidermal assays 2: 5
Cloning, epigenetic processes in 1: 63 1:
Cloning, epigenetic reprogramming in 1: 119—124
Cloning, nuclear transfer outcomes 1: 626—628 1:
Cloning, ring isolation 2: 14
Cloning, X-chromosome inactivation in 1: 63 (see also “Nuclear transfer cloning” “Reproductive “Therapeutic
Code of Federal Regulations 2: 804
Collagen 1: 285—286 1: 2: 2:
Collagen as ES cell culture substrate 1: 3f
Collagen in chondrogenesis 2: 435
Colony-forming assay 1: 414—415
Colony-forming units, erythrocyte 2: 356
Colony-forming units, fibroblastic 2: 416—417 2:
Colony-forming units, granulocyte and macrophage 2: 356
Colony-forming units, megakaryocyte 2: 356
Colony-forming units, myeloerythroid 2: 356 2:
Colony-forming units, spleen 2: 1 2: 2: 2:
Columnar cells 2: 522
Commercial development of stem cell technology 1: 787—792 1: 1: 2:
Common lymphoid progenitors 2: 87 2: 2:
Common lymphoid progenitors in CD8 generation 2: 361
Common lymphoid progenitors in dendritic cell ontogeny 2: 360—361
Common lymphoid progenitors in hematopoietic stem cell regulation 2: 25 2: 2:
Common lymphoid progenitors in lymphoid commitment 2: 356—358 2:
Common lymphoid progenitors in thymopoiesis 2: 351—352
Common lymphoid progenitors, alternative differentiation mechanisms 2: 351
Common lymphoid progenitors, clonal assays 2: 347
Common lymphoid progenitors, current conceptualization 2: 347 2: 2:
Common lymphoid progenitors, fetal liver 2: 365—366
Common lymphoid progenitors, functional lineage analysis 2: 349—350
Common lymphoid progenitors, GATA transcription factors in 2: 365
Common lymphoid progenitors, gene expression profile 2: 89 2: 2:
Common lymphoid progenitors, immunophenotype 2: 348 2: 2:
Common lymphoid progenitors, isolation and identification 2: 347—348
Common lymphoid progenitors, precursors 2: 95
Common lymphoid progenitors, transcription regulation 2: 95
Common myeloid progenitors 2: 87 2:
Common myeloid progenitors in bone marrow 2: 367—368 2:
Common myeloid progenitors in CD8 generation 2: 361
Common myeloid progenitors in dendritic cell ontogeny 2: 360—361
Common myeloid progenitors in hematopoietic stem cells 2: 115 2:
Common myeloid progenitors in lymphoid commitment 2: 364—366
Common myeloid progenitors in myeloerythroid commitment 2: 358—360
Common myeloid progenitors, clinical significance 2: 368—369
Common myeloid progenitors, current conceptualization 2: 347 2:
Common myeloid progenitors, fetal liver 2: 365—366
Common myeloid progenitors, gene expression profile 2: 89 2:
Common myeloid progenitors, transcription regulation 2: 95
Compaction 1: 129 1:
Connexins in ES cell differentiation 1: 102
Connexins in gap junction structure 1: 101 1:
Connexins, biological significance 1: 101
Connexins, characteristics 1: 101—102
Connexins, classification 1: 101 1:
Connexins, human diseases linked to mutations in 1: 104t
Connexins, structure 1: 101—102
Connexins, transcriptional regulation 1: 107
Cornea, epithelial transplant 2: 768
Cost of skin grafts 2: 768
Counterflow centrifugal elutriation 2: 616
CpG dinucleotides 1: 68 1: 1: 2:
Craniofacial structures, clinical potential of neural crest cells 2: 215
Craniofacial structures, morphogenesis 1: 224 1: 1: 1:
Cre-lox system 1: 547 1: 1: 1: 1: 1: 1: 1: 1: 2:
Cre-lox system, evidence of transdifferentiation 2: 155
Cre-lox system, neural crest cell fate mapping 2: 226 2:
Cre-lox system, satellite cell studies 2: 396—397
Cripto 1: 305—306
Crohn’s disease 2: 529—530
Cruciate ligaments 2: 776
Cryopreservation of blood 2: 182
Cryopreservation, embryoid body-derived cells 1: 468
Cryopreservation, embryonic fibroblasts 1: 537
Cryopreservation, embryonic germ cells 1: 454—455
Cryopreservation, ES cell samples 1: 426—427 1: 1: 1: 1: 1:
Cryopreservation, trophoblast stem cells 1: 481
Culture conditions for cell fusion 2: 153—154
Culture conditions for CNS cell replacement 2: 697—698
Culture conditions for osteoclast induction 1: 297—301 1:
Culture conditions for tissue engineering applications 1: 741 2:
Culture conditions, amniotic fluid 2: 175—176
Culture conditions, avian stem cells 1: 471—477
Culture conditions, bladder replacement cells 2: 565—566
Culture conditions, cardiomyocyte 1: 717—718 1:
Culture conditions, contamination 1: 438
Culture conditions, creating library of mutagenized cells 1: 602—603 1:
Culture conditions, differentiation of ES cells in adipocytes 1: 329—330 1:
Culture conditions, early ES cell research 1: 1—3
Culture conditions, EG cell derivation from primordial germ cells 1: 451—454 1:
Culture conditions, embryoid body mass culturing techniques 1: 333 1:
Culture conditions, embryonic carcinoma cells 1: 530—531
Culture conditions, ES/ESL cells 1: 20 1: 1:
Culture conditions, ES/ESL cells, feeder-free cultures 1: 431 1:
Culture conditions, ES/ESL cells, research needs 1: 529 1:
Culture conditions, hematopoietic progenitor cell separation and expansion 2: 618—619
Culture conditions, hematopoietic stem cell expansion 2: 622—623
Culture conditions, hepatocytes for transplantation 1: 359—360 1:
Culture conditions, Hoescht dye incubation 2: 330—331
Culture conditions, human ES cell derivation 1: 407 1: 1: 1: 1: 1:
Culture conditions, human ES cell derivation, safe practice 1: 779—781
Culture conditions, human ES cell derivation, subclones 1: 428
Culture conditions, human ES cell derivation, use of non-human feeder cell layers 1: 780—781
Culture conditions, inducing endothelial cell differentiation from ES cells 1: 317—321
Culture conditions, inducing ES cell differentiation to hematopoietic cells 1: 317—318 1:
Culture conditions, keratinocyte stem cells 2: 762 2:
Culture conditions, laminin-coated plates 1: 538
Culture conditions, long-term cultures 1: 489—490
Culture conditions, matrigel-coated plates 1: 538
Culture conditions, media components and recipes 1: 438—439
Culture conditions, melanocytes from ES cells 1: 233—235
Culture conditions, mesenchymal stem cells 2: 302
Culture conditions, monitoring 1: 437—438
Culture conditions, murine ES cells 1: 413—417
Culture conditions, muscle stem cells 2: 397
Culture conditions, myogenic stem cells 2: 574—577
Culture conditions, neural crest cell fates 2: 214
Culture conditions, neural differentiation of ES cells 1: 239—244 1: 1: 1:
Culture conditions, neural stem cells 1: 238—239 2:
Culture conditions, nuclear transfer cloning 1: 624
Culture conditions, pancreatic  -cells 2: 518
Culture conditions, polymer scaffolds 1: 367
Culture conditions, primate ES cell differentiation 1: 433—434
Culture conditions, processed lipoaspirate cells 2: 426—427 2:
Culture conditions, screening media 1: 439
Culture conditions, serum-free 1: 529—533
Culture conditions, spermatogonial stem cell maintenance 1: 179—180
Culture conditions, spinner flask cultures 1: 717—718
Culture conditions, stem cell expansion cultures 2: 663—671
Culture conditions, stem cell expansion cultures for tissue engineering 2: 784—785
Culture conditions, thymus epithelial cells 2: 557—558
Culture conditions, trophoblast stem cell lines 1: 197—200 1:
Culture conditions, trypsinization of human ES cell cultures 1: 442—446 1: 1: 1:
Culture conditions, use of bovine serum 1: 779—780
Culture conditions, vascular differentiation of ES cells 1: 318—321
Culture conditions, Xenopus animal cap cells 1: 483—491
Culture conditions, zebra fish ES cell derivation 1: 493—495
Cumulus cells 1: 644
|
|
|
| Ðåêëàìà |
|
|
|
|
|
|
|
|
Î ïðîåêòå